Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 6/20 | 0.51 |
| ▸ | CFD | P00746 | 3/20 | 0.40 |
| ▸ | PLAU | P00749 | 3/20 | 0.40 |
| ▸ | PLG | P00747 | 2/20 | 0.40 |
| ▸ | F11 | P03951 | 1/20 | 0.40 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.40 |
| ▸ | F7 | P08709 | 1/20 | 0.40 |
| ▸ | TPSB2 | P20231 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | PTP4A3 | O75365 | 2/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.33 |
| ▸ | PPARD | Q03181 | 3/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | XDH | P47989 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL629669 | 0.89 | PTPN1 (0.49) | PTPN1CFDPLAUPLGF11 | |
| SCHEMBL631155 | 0.87 | PTPN1 (0.51) | PTPN1CTSLCTSBPTP4A3FFAR1 | |
| SCHEMBL629847 | 0.85 | PTPN1 (0.49) | PTPN1FFAR1PPARD | |
| SCHEMBL629597 | 0.85 | PTPN1 (0.47) | PTPN1CFDFFAR1PPARDMAOB | |
| Potassium SCHEMBL629775 | 0.84 | PTPN1 (0.51) | PTPN1ABL1MAOB | |
| SCHEMBL629774 | 0.84 | PTPN1 (0.51) | PTPN1ABL1MAOB | |
| SCHEMBL629591 | 0.83 | PTPN1 (0.46) | PTPN1CTSLCTSBPTP4A3MAOB | |
| SCHEMBL3005189 | 0.83 | PTPN1 (0.48) | PTPN1MAOB | |
| SCHEMBL3006427 | 0.83 | PTPN1 (0.46) | PTPN1PTP4A3MAOB | |
| SCHEMBL629845 | 0.83 | PTPN1 (0.46) | PTPN1PTP4A3MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963292-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-02-22 | — | — | EP | disclosed |
| US-7700633-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-04-20 | — | — | US | disclosed |
| US-20080262050-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-10-23 | — | — | US | disclosed |
| EP-1963292-A2 | ORGANIC COMPOUNDS | Novartis Pharma AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007067615-A2 | THIADIAZOLE DERIVATIVES AS ANTIDIABETIC AGENTS | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262050-A1 | Organic Compounds | PTPRS, PTPRO, PTPRC | PTPN1 23/4885CFD 4819/4885PLAU 1751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.